Back to Search
Start Over
Real-world experience of brolucizumab in nAMD
- Source :
- Indian Journal of Ophthalmology, Vol 72, Iss 13, Pp 27-32 (2024)
- Publication Year :
- 2024
- Publisher :
- Wolters Kluwer Medknow Publications, 2024.
-
Abstract
- Purpose: To evaluate real-world outcomes with neovascular age-related macular degeneration (nAMD) in relation to anatomical success, visual outcomes, and safety of intravitreal brolucizumab (IVBr) injection at 1.5 years. Methods: Prospective, randomized, single-center study between December 2020 and December 2022 that included 71 eyes of 62 patients with nAMD, who received IVBr. Patients were divided into three groups, i.e., naïve choroidal neovascular membrane (CNVM), switched therapy (st) CNVM, and st polypoidal choroidal vasculopathy (stPCV). They were subdivided into dry, minimal fluid (fluid 100 microns)/PED subgroups depending upon the fluid level at the end of 1.5 years. Best-corrected visual acuity (BCVA), central macular thickness (CMT), status of fluid, and number of injections at 1.5 years were evaluated. From the beginning, patients were treated on pro re nata (PRN) basis. Results: Of the 71 eyes, 27 eyes (38%) were naïve CNVM, 35 eyes (49.3%) were stCNVM, and 9 (12.7%) were stPCV cases. Significant vision improvement after 1.5 years was seen in the stCNVM category (P = 0.001), while CMT reduction was significant in all three groups (P < 0.05). The mean number of injections required in naïve CNVM and stCNVM groups was significantly less as compared to the stPCV group (P = 0.017). Further, vision improvement was significant in the “Minimal fluid” subgroup (P = 0.002), while the CMT improvement was significant in the “Minimal fluid” and “Dry” subgroups each with P < 0.0001. No ocular/systemic adverse events including intraocular inflammation (IOI) were noted. Conclusion: In a real-world scenario, with 203 procedures and 1.5-year follow-up, brolucizumab is found to be efficacious and safe with the need for a lesser number of injections and more interval-free period in the management of naïve CNVM, stCNVM, and stPCV patients.
- Subjects :
- brolucizumab
cnvm
fluid
intraocular inflammation (ioi)
pcv
Ophthalmology
RE1-994
Subjects
Details
- Language :
- English
- ISSN :
- 03014738 and 19983689
- Volume :
- 72
- Issue :
- 13
- Database :
- Directory of Open Access Journals
- Journal :
- Indian Journal of Ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.3a8ec184908a494ca316a32097c06899
- Document Type :
- article
- Full Text :
- https://doi.org/10.4103/IJO.IJO_792_23